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ABSTRACT
Introduction: Osteonecrosis of the jaw has been consistently reported in the literature associated to the high-dose intravenous bisphosphonate 
therapy. However, osteonecrosis can also occur in patients who have other risk factors.
Case description: An unusual case of ONJ in a patient being treated with esomeprazole is reported.
Discussion: The probable association between proton pump inhibitor intake and osteonecrosis of the jaw should alert clinicians. Collaborations 
between medical and dental doctor and an early diagnosis might prevent or reduce the morbidity resulting from advanced destructive 
lesions of the jaw bone. 
LEARNING POINTS
• Osteonecrosis of the jaw (ONJ) can occur in patients treated with bisphosphonates and corticosteroids and is associated with oral 
surgical procedures involving bone.
•	 Antacid	drugs	commonly	used	to	treat	gastro-oesophageal	reflux	could	affect	bone	metabolism	although	no	cases	of	ONJ	in	patients	
using proton pump inhibitors have been reported.
• Medical and dental practitioners should collaborate to prevent ONJ, identify previously unreported drug interactions, and treat patients 
in a more comprehensive manner.
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INTRODUCTION
Osteonecrosis of the jaw (ONJ) has been consistently reported in the literature since the 19th century[1]. It is an uncommon clinical entity 
with several causes, including head and neck irradiation, chemotherapy, trauma and periodontal disease[2]. Over the last 10 years, an 
increasing number of case reports have suggested that high-dose intravenous bisphosphonates may be associated with ONJ[3]. Patients 
typically	presented	with	pain,	 impaired	healing	of	extraction	sockets,	or	exposed	bone.	Nearly	all	patients	 (86%)	had	undergone	dental	
procedures and most were receiving long-term chemotherapy and short-term intermittent corticosteroid treatment[3]. However, ONJ can 
also occur in patients who are not treated with bisphosphonates and in patients without the traditional risk factors[4]. The authors report an 
unusual case of ONJ in a patient being treated with esomeprazole.
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CASE DESCRIPTION 
A 72-year-old man was referred to the Istituto Stomatologico Toscano (Lido di Camaiore, Italy) in September 2017. The patient had a complete 
removable prosthesis in the lower jaw and a partial removable prosthesis in the upper jaw. He complained of a chronic painful swelling 
in	the	left	mandibular	area.	His	medical	history	revealed	intake	of	docetaxel	and	the	steroid	prednisone	over	a	3-year	period	following	a	
diagnosis	of	prostate	cancer.	Extra-oral	examination	did	not	reveal	any	facial	asymmetry.	However,	on	intra-oral	examination,	an	ulcerated	
area in the left lower jaw was noted after the prosthesis was removed (Fig. 1).	The	ulcer	was	exposing	necrotic	bone	at	 the	 level	of	 the	
alveolar	crest.	The	lesion	measured	approximately	2	cm	(mesiodistal)	by	1	cm	(buccal-lingual).	Radiographic	evaluation	showed	radiolucency	
in the corresponding area (Fig. 2). A provisional diagnosis of ONJ was made. After discussion with the patient, surgical debridement of the 
pathological	lesion	was	performed	under	local	anaesthesia	(2%	mepivacaine),	with	scraping	instruments	and	a	bone	cutting	forceps	(Fig. 3). 
The mouth of the patient was rinsed for 1,5 minute with ozonized water (Aquolab EB2C Srl), for decontamination purposes, prior to the 
surgery	and	amoxicillin	(500	mg	three	times	a	day	for	7	days)	and	metronidazole	(500	mg	three	times	a	day	for	7	days)	were	prescribed	to	
start the therapy before surgery. However, 3 months after surgery, the lesion had not healed and the patient was complaining of a moderate 
ache at the site of intervention. 
Figure 1. Clinical view of exposed necrotic bone at the first examination
Figure 2. Panoramic radiography of the patient’s jaw at the first examination
Figure 3. Intra-operative photograph (first surgical procedure)
It was decided to reconsider the possible side-effects and interactions of the drugs currently used by the patient. Further enquiry revealed 
that	the	patient	was	a	long-term	user	of	an	over-the-counter	proton	pump	inhibitor	(PPI;	Nexium,	AstraZeneca,	Basiglio,	Milan,	Italy)	for	the	
symptomatic	treatment	of	gastro-oesophageal	reflux.	PPIs	interfere	with	bone	metabolism,	as	acknowledged	by	the	FDA.	It	was	therefore	
decided	to	immediately	stop	the	antacid	drug	and	to	excise	the	necrotic	bone,	with	scraping	of	the	affected	area	in	order	to	reach	healthy	
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bleeding bone (Fig. 4). The necrotic area was treated with local ozone therapy (Ozone DTA, Sweden & Martina S.p.A.) 2 days before surgery, 
and	then	once	a	day	for	the	first	week	after	surgery,	followed	by	once	a	week	for	the	next	2	months.	Histological	analysis	of	the	excised	bone	
confirmed	the	diagnosis	of	ONJ.	A	second	cycle	of	antibiotic	therapy	was	prescribed	(amoxicillin	500	mg	four	times	a	day	for	5	days)	with	
chlorhexidine	gluconate	0.2%	for	mouth	rinsing.	The	patient’s	symptoms	resolved	and	the	soft	tissues	had	healed	completely	after	2	months	
(Fig. 5).	The	patient	returned	for	follow-up	visits	at	6	months	and	12	months	with	no	adverse	events	recorded.	
Figure 4. Intra-operative photograph (second surgical procedure) Figure 5.Healed tissues 2 months after the second surgical procedure and the suspension 
of proton pump inhibitor therapy 
DISCUSSION
PPIs are commonly prescribed worldwide[5]	and	frequently	used	to	treat	gastro-intestinal	disorders	such	as	acid	reflux	and	ulcers.	They	
suppress the functions of the proton pump (H1/K1 ATPase), thus inhibiting gastric acidity[6]. Adverse effects, such as increased risk of 
infections, interaction with other drugs, dementia and reduced mineral absorption have been reported[7,8]. Reports have also shown that 
PPIs can impair bone metabolism: (a) the suppression of gastric acidity results in a reduction in intestinal calcium uptake and (b) PPIs down-
regulate osteoclastic activity by inhibiting their surface proton pumps[9]. 
Our	patient	presented	with	jaw	osteonecrosis	which	resolved	after	suspension	of	antacid	therapy	with	esomeprazole	(Nexium).	A	recent	
cohort	 study,	 which	 included	 over	 60,000	 alendronate	 users	 in	 Denmark,	 investigated	 the	 presence	 of	 potential	 risk	 factors	 for	 ONJ	
requiring surgical treatment[10]. The authors suggested that ONJ risk appeared to be higher in patients with concomitant risk factors other 
than bisphosphonate treatment: a history of rheumatoid disease and the use of PPIs were independently associated with surgically treated 
ONJ.	The	esomeprazole	Nexium	is	one	of	the	most	commonly	used	PPIs	and	it	is	often	taken	together	with	non-steroidal	anti-inflammatory	
drugs (NSAIDs). Furthermore, NSAIDs are frequently prescribed for pain control after oral surgery, and their usage is also related to bone 
health[11]. In brief, adult patients who have a positive history of bisphosphonate use, cancer and oral surgery might be more likely to use PPIs 
and NSAIDs, and, therefore, be more prone to ONJ. 
Recent cohort studies on dental implant outcomes have suggested that PPI intake is associated with an increased risk of implant failure [12]. 
This association persisted after adjustment for multiple confounding factors[13]. Furthermore, study participants in implant programs had 
not	included	patients	treated	with	bisphosphonates,	since	this	was	one	of	the	exclusion	criteria[14].
Long-term	use	of	PPIs	is	associated	with	reduced	serum	levels	of	calcium	and	vitamin	B12,	impaired	collagen	deposition	in	the	extracellular	
matrix,	and	reduced	bone	strength.	Recent	evidence	has	also	supported	a	gene	modulating	effect	by	PPIs	towards	lower	expression	of	bone	
formation markers. 
The observation of an association between PPI intake and ONJ should alert practitioners[15]. An early diagnosis might prevent or reduce 
the morbidity resulting from advanced destructive lesions of the jaw bone. Furthermore, osteoclast-selective PPIs may be an interesting 
anti-resorptive agent for future study.
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